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Summary. Background: Although routine coagulation monitoring is unnecessary, measuring plasma dabigatran concentrations can be useful for detecting drug accumulation in renal failure or overdose, assessing the contribution of dabigatran to serious bleeding, planning the timing of urgent surgery or intervention, or determining the suitability for thrombolytic therapy for acute ischemic stroke. Dabigatran concentrations can be quantified using chromogenic or clot-based tests, such as the ecarin chromogenic assay (ECA) and the diluted thrombin time (dTT), respectively. Objective: The purpose of this study was to compare the results of these assays with dabigatran concentrations measured by the reference standard of mass spectrometry in samples from 50 dabigatran-treated patients collected at peak and trough after at least 4 months of drug intake. Methods: Drug levels measured with either the STA Ecarin Chromogenic Assay-II (STA-ECA-II) or dTT were linearly correlated with those determined by mass spectrometry over a wide range of concentrations. Results and Conclusions: For detection of levels below 50 ng mL À1 both tests have specificities of at least
Introduction
Dabigatran is an oral direct thrombin inhibitor that is licensed for stroke prevention in non-valvular atrial fibrillation, for prevention of venous thromboembolism after elective hip or knee arthroplasty, and for treatment and secondary prevention of venous thromboembolism. When given in fixed doses without coagulation monitoring, dabigatran was at least as effective as warfarin for stroke prevention in non-valvular atrial fibrillation and for treatment of venous thromboembolism and was associated with less serious bleeding, particularly less intracranial hemorrhage [1, 2] . Although routine coagulation monitoring is not indicated, measuring plasma dabigatran concentrations can be useful for detection of drug accumulation in the setting of acute renal failure or overdose, assessing the contribution of dabigatran to serious bleeding, planning the timing of urgent surgery or intervention, or determining the suitability for thrombolytic therapy for acute ischemic stroke [3, 4] . Detection of low levels of dabigatran is particularly important for the latter indications.
Readily available global tests of coagulation, such as the activated partial thromboplastin time (APTT) and the thrombin time (TT), provide only qualitative information. Although the APTT may provide information on the absence or presence of dabigatran, the APTT plateaus with higher dabigatran concentrations and the test may be normal in some patients with clinically relevant plasma concentrations of dabigatran [5] . Furthermore, the responsiveness of the APTT to dabigatran is reagent dependent, which complicates the interpretation of the results [6] . Nonetheless, a prolonged APTT in a dabigatran-treated patient who presents with serious bleeding or is in need of urgent surgery is sufficient grounds for reversal with idarucizumab. The TT also is problematic because it lacks standardization, is prolonged with low concentrations of dabigatran, and is immeasurable with therapeutic concentrations [5] . Therefore, routine global tests of coagulation are of limited value for determining the anticoagulant effects of dabigatran.
Dabigatran concentrations can be quantified using clot-based or chromogenic assays. The clot-based assays include the diluted thrombin time (dTT) and the ecarin clotting time (ECT). Both tests have previously been shown to correlate with dabigatran concentrations measured by mass spectrometry and both were used as markers of dabigatran reversal with idarucizumab, the antidote for dabigatran, in the Reversal Effects of Idarucizumab in Patients on Active Dabigatran (RE-VERSE AD) study [7, 8] . Dabigatran concentrations can also be quantified with the STA-ecarin chromogenic assay-II (STA-ECA-II) [9] . Chromogenic antifactor Xa assays are recommended for quantification of plasma concentrations of rivaroxaban, apixaban and edoxaban [10] [11] [12] [13] [14] , and the STA-ECA-II enables measurement of dabigatran concentrations on a similar platform.
Although the ECA and the dTT have been adapted for quantification of dabigatran concentrations [9, [14] [15] [16] [17] [18] , the agreement between the STA-ECA-II and dabigatran concentrations measured using the reference standard of high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS) has not been directly compared with that of the dTT over a broad range of dabigatran concentrations. Furthermore, the two tests have never been compared head-to-head in samples collected from patients taking dabigatran. The purpose of this paper was to perform these comparisons with a view to identifying the minimum levels of detection and calculating the sensitivity and specificity of these tests in patients taking dabigatran.
Methods

Plasma samples
Plasma samples from dabigatran-treated patients were selected from those obtained as part of a dabigatran plasma concentration variability study, the details of which have been previously published [19] . Briefly, peak and trough blood samples were collected from atrial fibrillation patients taking 110 or 150 mg of dabigatran twice daily [19] . Blood for peak level determination was taken 2.5 h (AE 10 min) after morning dabigatran administration, whereas blood for trough level determination was collected at a median of 13.3 AE 4.7 h after the previous evening dose of dabigatran. In both cases, blood was collected into 5-mL Vacutainer tubes (Becton Dickinson, Mississauga, ON, USA) containing 0.5 mL of 3.2% buffered trisodium citrate. After inverting the tubes three to five times to ensure mixing, cellular elements were sedimented by twice subjecting the samples to centrifugation at 1700 9 g for 15 min at 23°C and the resultant platelet-poor plasma was then harvested and stored in 1-mL aliquots at À80°C. The study protocol was approved by the Hamilton Integrated Research Ethics Board and all patients provided informed written consent. For the current study, peak and trough samples from 50 patients who had been on dabigatran for at least 4 months were selected randomly.
Quantification of dabigatran concentrations
The STA-ECA-II was performed using the STA STA-ECA-II II kit with STA dabigatran calibrators (0, 52, 106, 182 and 270 ng mL À1 ) and a Stago STA-R Evolution coagulation analyzer (Diagnostica Stago, Asni eres sur Seine, France) according to the manufacturer's instructions. The dTT was performed using the Hemoclot Ò Thrombin Inhibitor Assay (Hyphen BioMed, Neuville-sur-Oise, France) as previously described [20] . Total dabigatran concentrations were quantified using HPLC-MS by Nuvisan Pharma Services (Neu-Ulm, Germany) as described by Stangier and colleagues [21] . Aliquots of stored plasma were thawed and dabigatran concentrations were quantified using the STA-ECA-II. The previously measured dTT values used in the dabigatran variability study [19] were used for this analysis. To verify that the dabigatran concentrations measured by dTT were unaffected by storage, 10 samples selected at random underwent repeat dTT determination contemporaneously with the STA-ECA-II measurements, and the results were compared with those previously obtained. By referring to a standard curve constructed using dabigatran calibrators, STA-ECA-II or dTT results were converted to dabigatran concentrations in ng mL
À1
. Both assays were performed in duplicate; however, because one assay would be carried out in typical clinical practice, only the first determination was used for statistical purposes. Dabigatran concentrations measured with the STA-ECA-II and dTT were then compared with those determined using HPLC-MS.
Statistical analysis
Regression analysis was used to characterize the relationship between the STA-ECA-II or dTT results and the corresponding dabigatran levels determined by HPLC-MS.
Both simple linear and multivariable models were used and a quadratic term was incorporated to detect evidence of non-linearity. If the relationship was determined to be linear, agreement was assessed by comparing the fitted slope to unity and the paired mean difference with HPLC-MS to zero. The presence of either a slope different from one or a mean difference would indicate bias with respect to HPLC-MS. Bland-Altman plots were also constructed as supportive analyses [22] . To determine whether the STA-ECA-II and dTT assays reliably identify low levels of dabigatran, receiveroperator curves (ROCs) for HPLC-MS values below 50 or 30 ng mL À1 were constructed. These dabigatran cutoffs were chosen to align with industry submissions to the European Medicines Agency consensus statements and guidelines that identify 50 and 30 ng mL À1 as the dabigatran concentration below which surgery can be performed and thrombolytic therapy can be administered, respectively [23] [24] [25] . We calculated the areas under the ROCs as a general measure of accuracy and compared areas between the STA-ECA-II and dTT assays. In addition, the sensitivity and specificity (reported as percentages) of the STA-ECA-II and dTT assays were calculated at the prespecified cut-offs of 50 and 30 ng mL 
Results
Correlation of the STA-ECA-II with HPLC-MS
The relationship between the STA-ECA-II and HPLC-MS results is shown in Fig. 1(A) . Regression analysis reveals a significant (P < 0.001) non-linear association resulting in clear upward bias as the level determined by HPLC-MS increases. The non-linearity with samples with dabigatran concentrations above 250 ng mL À1 may have been introduced by the automated dilution that is performed by the STA-R coagulometer when dabigatran concentrations exceed 270 ng mL À1 . Figure 1(B) shows the relationship at dabigatran levels ≤ 100 ng mL À1 measured by HPLC-MS. This range was selected because it incorporates the expected median trough levels of dabigatran at steady state [26, 27] . At these concentrations, the STA-ECA-II is linear (y = 1.049 À 4.36) and highly correlated with the results measured by HPLC-MS, with a slope that is not significantly different from unity (P = 1.00), but with a significant bias that causes the STA-ECA-II to underestimate the level determined by HPLC-MS by 4.4 ng mL À1 (95% confidence interval [CI] À3.3 to À5.6; P < 0.001). Figure 1(C) shows the relationship at dabigatran levels ≤ 250 ng mL À1 measured by HPLC-MS. This range was selected because it incorporates median therapeutic peak levels of dabigatran [26, 27] . Within these concentrations, the STA-ECA-II continues to be linear and remains highly correlated with the results of HPLC-MS. Whereas the STA-ECA-II underestimates dabigatran levels at low concentrations, there is a slight overestimation at high levels as a result of the fitted slope (1.08) being significantly different than unity (P < 0.0001). The corresponding Bland-Altman plots of the paired difference between STA-ECA-II and HPLC-MS against the average of the two assays are shown in Fig. 2(A-C) .
Correlation of the dTT with HPLC-MS
To first confirm that the previously measured dTT results were unaltered by storage, the dTT was repeated in 10 randomly selected samples. Comparison of the new dTT values with those previously determined yielded an R 2 value of 0.989, consistent with a high degree of correlation. Bland-Altman analysis (Fig. S1 ) confirms the excellent agreement between the original and the repeated measurements. Thus, the mean difference between measurements was 0.9 ng mL À1 (95% CI, À25.4 to 27.1 ng mL À1 ). Therefore, significant bias as a result of dabigatran degradation during storage was unlikely and the previously measured dTT values were used for subsequent analyses. The relationship between the dTT and HPLC-MS is illustrated in Fig. 3 . Figure 3(A) , which displays all data points, shows little evidence of non-linearity (P = 0.44) and a linear model (y = 1.13 9 À 0.23) fit the dTT assay well but with a slope that was significantly greater than one (P < 0.001) with increasing upward bias at higher dabigatran concentrations as measured by HPLC-MS. With HPLC-MS-determined dabigatran concentrations ≤ 100 ng mL
À1
, there was a highly significant (P < 0.001) linear relationship (y = 1.01 9 + 6.49) between the dTT and HPLC-MS results (Fig. 3B) , with a slope that was not significantly different from unity (P = 0.86), but with upward displacement from the line of complete agreement with an overestimation of dabigatran concentrations by dTT of 7.0 ng mL À1 (95% CI, 4.3-9.8; P < 0.001). , again demonstrates that the slope of the fitted line is linear with a highly significant relationship (P < 0.001), but with an increasing overestimation of dabigatran concentrations. This is a result of the estimated slope (1.13) being significantly (P < 0.0001) greater than unity. The corresponding Bland-Altman plots for the dTT assay are shown in Fig. 4(A-C) .
Using the data generated from Figs 1(C) and 3(C), we calculated the mean bias of the STA-ECA-II and dTT (Table 1) . Although there is a change in the estimation of STA-ECA-II from underestimation to overestimation with increasing dabigatran concentrations, and an ongoing overestimation of dabigatran concentrations with the dTT, these variances are small at low drug concentrations where they are most likely to influence clinical decisions. Moreover, at dabigatran concentrations greater than 250 ng mL À1 , the STA-ECA-II more closely estimates the HPLC-MS than the dTT (mean biases, 12.5 vs. 31.7 ng mL À1 ) ( Table 1 ). These findings are consistent with the observation that at the upper end of the range, there is a widening divergence between the STA-ECA-II and dTT. The capacity to measure low levels of dabigatran is important prior to major surgery, particularly if neuraxial anesthesia is contemplated, or when considering eligibility for thrombolytic therapy. Figures 5 and 6 show the distribution of individual STA-ECA-II and dTT values and their corresponding HPLC-MS dabigatran levels for levels ≤ 50 ng mL À1 and ≤ 30 ng mL
, respectively. Figure 5 reveals the small number of results for either the STA-ECA-II or the dTT that could be classified as falsepositive, meaning that they incorrectly measure the dabigatran concentrations to be less than 50 ng mL À1 , whereas by HPLC-MS the concentrations are over 50 ng mL
. Consequently, the sensitivities of these tests at the 50-ng mL À1 cut-off (i.e. their capacity to measure dabigatran concentrations less than 50 ng mL À1 ) are 99%
and 85%, respectively, and their specificities (i.e. the ability of the test to accurately identify dabigatran concentrations above 50 ng mL À1 ) are 96% and 99%, respectively, values not statistically significantly different from each other. At the lower cut-point of 30 ng mL À1 (Fig. 6) , there are again a few false-positive results and at this cutpoint, the sensitivities for the STA-ECA-II and dTT are 91% and 73%, respectively, whereas their specificities are 97% and 99%, respectively. These results are not significantly different, but this determination is based on a small number of observations. At both of the evaluated cut-points, the STA-ECA-II and the dTT have high specificities, thereby confirming their utility for detecting concentrations of dabigatran above 50 ng mL
.
Discussion
We compared the performance of the STA-ECA-II-II and the dTT for quantification of plasma dabigatran concentrations in samples collected from patients taking the drug. We found good agreement between the results of both tests and drug concentrations measured using HPLC-MS, the reference standard, over a wide range of dabigatran levels. Compared with HPLC-MS, both tests slightly overestimate dabigatran concentrations above the therapeutic range. However, this finding does not undermine the value of the tests because, when making clinical decisions, accurate quantification of high levels is less important than quantification of low levels. At dabigatran concentrations ≤ 100 ng mL À1 , which encompasses expected trough levels, the STA-ECA-II assay tends to be more accurate than the dTT because of its higher correlation (0.99 and 0.94, respectively) and smaller mean bias (4.4 and 7.0 ng mL
À1
, respectively), but neither of these differences is statistically significant. Likewise, with dabigatran concentrations ≤ 250 ng mL À1 , which encompasses expected peak levels, the results of the STA-ECA-II-II and dTT assays continue to be highly correlated with those determined by HPLC-MS and the differences between them are not statistically significant. These observations demonstrate the utility of both tests for quantification of dabigatran concentrations across the expected on-treatment range.
Our results are in agreement with those reported by other investigators [28] [29] [30] . Using plasma samples to which dabigatran was added, Gosselin et al. reported that the ECA had high specificity and correlated with dabigatran levels measured by HPLC-MS with an R 2 value of 0.998 [29] . In agreement with our findings, at low levels of dabigatran, they reported that the ECA tended to underestimate the values compared with HPLC-MS [11, 29] . Like us, however, they questioned the clinical significance of this finding. Using plasma samples from a total of 33 patients, Douxfils et al. noted good correlation between the STA-ECA-II and HPLC-MS results with dabigatran concentrations in the 17 samples with levels below 50 ng mL À1 [28] . To achieve this correlation with the dTT, however, additional low concentration calibrators were required using the HTI LOW kit [28] . With a larger number of patient samples, we found that even the unmodified dTT had adequate sensitivity for detection of dabigatran levels below 50 ng mL À1 . Detection of low levels of dabigatran is important when considering the use of idarucizumab for dabigatran reversal, planning the timing of urgent surgery or intervention or when determining the suitability for thrombolytic therapy for acute ischemic stroke. Although testing is not essential prior to idarucizumab administration, reversal is unlikely to be of benefit if the dabigatran concentration is below 30 ng mL À1 , and surgery is likely to be safe if levels are below 50 ng mL À1 [25] . Accordingly, we evaluated test performance data at cut-offs of 50 and [28, 31] . Using a modification of ROC analyses ( Figs 5 and 6 ), we show that both the dTT and STA-ECA-II-II correctly identify dabigatran levels at these cut-offs. We used this type of analysis because it aids in clinical decision making. Although Bland-Altman analyses are often used to compare assay results, sensitivity and specificity are more widely understood by clinicians. Nonetheless, regardless of the method of analysis, our data suggest that both the STA-ECA-II-II and dTT accurately measure low and usual on-treatment levels of dabigatran. Unfortunately, neither the dTT nor the STA-ECA-II-II is currently licensed for clinical use by the United States Food and Drug Administration. Although the tests are approved in other jurisdictions, they are not widely or rapidly available in most hospitals. In addition, the lack of international standards for calibration of dabigatran reference materials may be a source of inter-assay and inter-laboratory variability in results. Cooperation among regulators, standardization committees and hospitals is urgently needed to make such tests readily available to improve monitoring for patients taking direct oral anticoagulants.
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